Improving growth and development in children with growth hormone deficiency through transdermal treatment of acupoints with the tonifying spleen and kidney method in conjunction with growth hormone therapy.

Abstract

This retrospective analysis aimed to evaluate the potential benefits of integrating transdermal acupoint therapy with the tonifying spleen and kidney method alongside growth hormone (GH) treatment for pediatric patients suffering from growth hormone deficiency (GHD). Clinical data of 115 pediatric patients with GHD were retrospectively analyzed. Patients were categorized into two distinct groups for the analysis: The conventional GH treatment group (n=62) and the combined group of acupoint transdermal therapy alongside GH treatment (n=53). Baseline characteristics, hormone levels, bone mineral density (BMD), physical growth parameters and adverse events were compared. The baseline characteristics of the two groups were well-matched. After one year of treatment, the combined group showed significantly lower levels of insulin-like growth factor-1 (P<0.001), testosterone (P<0.001), estrogen (P<0.001), thyroid-stimulating hormone (P<0.001), insulin-like growth factor binding protein-3 (P=0.009) and free thyroxine (P<0.001) compared to the conventional group. The transdermal treatment group demonstrated significantly higher BMD at multiple sites (P<0.05) and improved physical growth parameters (P<0.05) compared to the conventional group. Furthermore, the transdermal treatment was not linked to a higher occurrence of adverse incidents and showed significant correlations with various growth and development indexes (P<0.05). Combined therapy showed promising effects on endocrine function and physical growth.